ArticleClinical and experimental hepatology2022

Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients.

Satoshi Shinozaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.